SCHEMBL6788504

SCHEMBL6788504

Cn1c2c(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)SC(C(=O)NCc1ccc(F)cc1)C(=O)N2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
LMNA P02545 3/20 0.39
TRPA1 O75762 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
P2RX7 Q99572 2/20 0.37
MCHR1 Q99705 1/20 0.37
TSHR P16473 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 2/20 0.36
MAPT P10636 3/20 0.35
HTR7 P34969 1/20 0.34
GPR18 Q14330 1/20 0.34
HPGD P15428 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PKM P14618 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679197 0.89 ALDH1A1 (0.49) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL6789742 0.86 LMNA (0.40) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL6678209 0.85 ALDH1A1 (0.38) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL6683259 0.84 ALDH1A1 (0.35) ALDH1A1KMT2ATSHRNPSR1PKM
SCHEMBL7123002 0.82 ALDH1A1 (0.38) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL7130471 0.80 ALDH1A1 (0.37) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL6679503 0.80 TRPA1 (0.42) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL6684431 0.76 KMT2A (0.49) ALDH1A1LMNAMEN1KMT2ACYP3A4
SCHEMBL6789030 0.73 L3MBTL1 (0.42) ALDH1A1LMNATRPA1MEN1KMT2A
SCHEMBL7127312 0.71 ALDH1A1 (0.49) ALDH1A1LMNATRPA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 ALDH1A1 812/4885LMNA 3842/4885TRPA1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.